ASC22 (Envafolimab) for Chronic Hepatitis B in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2023 & 2024-2032 - ResearchAndMarkets.com
"ASC22 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about ASC22 for chronic hepatitis B in the seven major markets and China.
- "ASC22 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about ASC22 for chronic hepatitis B in the seven major markets and China.
- Further, it also consists of future market assessments inclusive of the ASC22 market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.
ASC22, also known as envafolimab, is a first-in-class, subcutaneously administered PD-L1 antibody for chronic hepatitis B (CHB) functional cure. - Other emerging products for chronic hepatitis B are expected to give tough market competition to ASC22 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- What are the other emerging products available and how are these giving competition to ASC22 for chronic hepatitis B?